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OBJECTIVES: Pharmacy beneﬁt managers (PBMs) market their
ability to accelerate use of newly-approved generic drugs among
enrollees based upon the use of the PBMs’ wholly-owned mail
order drug facilities. Higher utilization rates of newly-approved
generic drugs result in an economic beneﬁt to enrollees and
plans. This study examines the differences in the diffusion of a
newly-approved generic drug product between mail order and
retail pharmacy channels. METHODS: Pharmacy claims data
for branded and generic versions of citalopram were collected
from a large state employee prescription drug program in Texas
consisting of over 400,000 enrollees beginning in November
2004 (representing the launch date of the newly-approved
generic). In addition, claims data were collected from the Texas
Medicaid Prescription Program during the same time period, for
comparison. Claims were collected for the ﬁrst six months post-
generic launch. Total outstanding “drug product in possession”
was calculated for each day post-generic launch based upon a
sum of the days supply for the branded and generic drug for
claims dispensed previous to, and during, the post-launch period.
Trends were examined in the percent of total outstanding days
supply represented by the branded or generic citalopram.
RESULTS: At days 30, 60, 90, and 120 post-generic drug launch,
percentage of generic drug product utilization (based upon out-
standing days supply) for mail order claims was 22%, 53%,
91%, and 96%. Retail claims showed generic utilization of 52%,
70%, 74%, and 78%. Medicaid program rates were 9%, 37%,
56% and 72%, respectively. Mail order generic utilization rates
of citalopram were lower than retail pharmacy utilization rates
until day 77 post-generic drug launch. CONCLUSIONS: While
the mail order pharmacy channel realized higher utilization rates
over the retail pharmacy channel of a newly-approved generic
drug product at four months post-launch, rates were higher in
retail setting during the ﬁrst 11 weeks.
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OBJECTIVES: Frequent rehospitalizations characterize the
course of schizophrenia. Though, knowledge about the impor-
tance of potential predictors for rehospitalization is limited. In
order to identify such predictors, the course of disease in schizo-
phrenic patients was analysed. METHODS: Claims data of a large
German sickness fund for the years 2000 to 2003 were used. A
sample of 2023 patients with an index hospitalization due to
schizophrenia (ICD-10: F20, F25) was drawn. The minimum
observation time for beneﬁciaries had to be 360 days. Cox-regres-
sion analysis was performed to estimate predictors for rehospi-
talization. RESULTS: A total of 1095 patients (54.1%) were
readmitted to hospital after 635 days (median). After discharge,
median duration until further hospitalization was 400 days (3rd
hospitalization), 287 days (4th hospitalization) and 160 days (5th
hospitalization), respectively. Patients with index hospitalizations
showed a signiﬁcantly higher risk for rehospitalization if they had
an inpatient stay due to acute exacerbation compared to patients
with rehabilitative care (relative risk (RR) 3.25; 95%CI
1.91–5.51; p < 0.001). Further predictors of rehospitalizations
were: substance abuse (RR 1.87; 95%CI 1.39–2.51; p < 0.001)
and duration of the index-case longer than 30 days. Patients with
schizoaffective disorders (ICD-10: F25) had a signiﬁcantly lower
risk than patients with schizophrenia (ICD-10: F20) (RR 0.58;
95%CI 0.46–0.74; p < 0.001). A lower risk was also observed in
beneﬁciaries aged 60 years and older (RR 0.50; 95%CI
0.33–0.75; p = 0.11). CONCLUSION: The following predictors
for rehospitalization have been identiﬁed: former hospitalization
due to acute exacerbation, duration of previous hospitalization,
younger age, and substance abuse. The more cases were observed,
the shorter the intervals between two hospitalizations became.
This illustrates the dynamics of the course of schizophrenia which
can be observed in longitudinal analyses of claims data.
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OBJECTIVES: To assess physicians’ antipsychotic drug pre-
scribing practices, patient descriptions, and perceptions of nega-
tive symptoms. METHODS: Psychiatrists in the United States
and 5 European countries who prescribed antipsychotics for ≥15
patients with schizophrenia within the preceding 3 months com-
pleted a questionnaire concerning their patients’ clinical status
and therapy. RESULTS: Data for 6523 patients were collected
from 872 physicians. Two thirds of patients were outpatients,
63% were men, most were aged 25–44 years, and 50% were
unemployed. 50% of patients were rated as moderately to
grossly dysfunctional; 34% and 75% were taking conventional
or atypical antipsychotics, respectively. The most frequent nega-
tive symptoms were social withdrawal (54%), impoverished
thought (39%), and blunted affect (38%). Reasons for prescrib-
ing antipsychotic drugs included efﬁcacy for positive symptoms
(90%), efﬁcacy for negative symptoms (62%), and tolerability
(47%). Inadequate control of symptoms was higher for negative
symptoms (71%–77%) than for positive symptoms (47%–60%);
physicians viewed currently available atypical antipsychotics as
less effective against negative than positive symptoms but more
effective than conventional antipsychotics for negative symp-
toms. Adverse events associated with patients’ current antipsy-
chotic treatment included sedation (22%), weight gain (22%),
and extrapyramidal symptoms/parkinsonism (13%). A total of
579 patients (9%) were categorized as having predominant 
negative symptoms. In this patient subset, negative symptoms
occurred more often than positive symptoms, were more often
the reason for prescription, and were less likely to be adequately
controlled. However, use of atypical antipsychotics was similar
to use in other patients. CONCLUSIONS: This large, multina-
tional, cross-sectional physician survey involving a naturalistic
sample of patients with schizophrenia identiﬁed more effective
treatment of negative symptoms as a key unmet need, especially
in patients with predominant negative symptoms.
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